TY  - JOUR
AU  - Song, Sang-Yun
AU  - Park, Cheol-Kyu
AU  - Oh, In-Jae
AU  - Kim, Young-Chul
PY  - 2017
TI  - Angiogenesis inhibitors for small cell lung cancer
JF  - Translational Cancer Research; Vol 6, Supplement 3 (May 26, 2017): Translational Cancer Research
Y2  - 2017
KW  - 
N2  - Small-cell lung cancer (SCLC) accounts for approximately 12–15% of all lung cancers and is characterized by a rapid growth rate and metastasis at the time of diagnosis. Despite its initial sensitivity to first-line chemotherapy, rapid acquisition of resistance to subsequent lines of therapy is usually observed. Although there is a plethora of new drugs being developed for non-small cell lung cancer (NSCLC), there is still a shortage of treatment regimens other than the combination therapy containing platinum and etoposide or irinotecan.
UR  - https://tcr.amegroups.org/article/view/13386